eurocoeliac disease: Prevalence, diagnosis, treatment and follow up

Recruiting

Conditions: Gluten ataxia
neurocoeliac disease
10017943
10003816
10028037

Registration Number: NL-OMON47970

Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 200

Inclusion Criteria

- * 18 years of age
- Given informed consent
- unexplained ataxia
- Group specific:
o For gluten sensitivity group: at least positive serology or borderline
positive serology
o For coeliac disease group: positive serology and positive biopsy results

Exclusion Criteria

- No informed consent
- Insufficient knowledge of Dutch language and/or inability to understand the
information provided.
- A known and verified cause of the neurological illness
- For MRI specific: Because of the high magnetic field of the MRI scanner,
individuals with pacemakers, metallic implants, pregnancy, or certain other
conditions (for example a bodyweight over a 140kg) should be excluded unless
they are cleared by a clinical radiologist/physiologist.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study endpoint will be the prevalence of (neuro)coeliac disease<br /><br>related antibody titres in the neurology cohorts, together with the HLA-DQ type<br /><br>and the Marsh classification based on a gastroduodenal biopsy (only if a biopsy<br /><br>has been performed as standard care).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints will be the effect of a gluten-free diet on antibody<br /><br>titres, neurological symptoms, quality of life and MRI and MR spectroscopy<br /><br>results in patients suspected of gluten ataxia.</p><br>